In particular the combination of CD133 and CD90 overexpression was associated with a reduced PFS (2.7 vs. 5.5 months, p = 0.04) suggesting a possible role of these genes as future biomarkers in the prediction of HCC response to chemotherapy (Figure 1) [107]. This evidence concerns the gene THY1 and hepatocellular carcinoma.